On April 12, 2024, AEON Biopharma, Inc. closed the transaction. The company issued one senior secured convertible note in the principal amount of $10,000,000 for a gross proceeds $10,000,000 in its final tranche. The Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date of April 12, 2027, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date.